Furthermore , this therapy could increase the dem and on radiation re sources .
There is no evidence on which to make a recommendation for patients with node-negative tumours that have not penetrated the muscularis propria .
For patients unable to undergo radiation , adjuvant chemotherapy alone may be of benefit , particularly for those with lymph-node metastases .
There is insufficient evidence from r and omized trials to recommend neoadjuvant chemotherapy , or neoadjuvant or adjuvant radiotherapy or immunotherapy , either alone or in combination , outside a clinical trial .
OBJECTIVE To make recommendations on the use of neoadjuvant or adjuvant therapy in addition to surgery in patients with resectable gastric cancer ( T1 - 4 , N1 - 2 , M0 ) .
OPTIONS Neoadjuvant or adjuvant treatments compared with " curative " surgery alone .
OUTCOMES Overall survival , disease-free survival , and adverse effects .
The radiation fields used can possibly damage the left kidney , result ing in hypertension and other renal problems .
[A randomized controlled trial of surgical adjuvant therapy with mitomycin C, 5-fluorouracil and OK-432 in patients with gastric cancer].
The effect of postoperative immunochemotherapy with mitomycin C ( MMC ) , 5-fluorouracil ( 5-FU ) and OK-432 was evaluated as an adjuvant therapy after curative resection for gastric cancer . Immediately after surgery , patients were r and omly allocated to the following three treatments : ( A ) chemotherapy with MMC and 5-FU ( 32 cases ) ; ( B ) chemoimmunotherapy with MMC , 5-FU and OK-432 ( 33 cases ) ; and ( C ) surgery alone as control ( 34 cases ) . There were no significant differences in the background factors influencing survival time among the groups , and there was no dose-distribution of chemotherapeutic agents between groups A and B. While the differences were not statistically significant , the survival rate and disease-free interval of group B were better than those of groups A or C. Side effects such as gastroenteric disorder , leukopenia ( less than 3,000/mm3 ) , thrombocytopenia ( less than 7 X 10(4)/mm3 ) and increase of serum transaminase level ( GPT greater than or equal to 100 units ) were less frequently observed in group B than in group A. The results of the present study seemed to indicate that chemoimmunotherapy with OK-432 may be effective for surgical adjuvant therapy
Furthermore , this therapy could increase the dem and on radiation re sources .
There is no evidence on which to make a recommendation for patients with node-negative tumours that have not penetrated the muscularis propria .
For patients unable to undergo radiation , adjuvant chemotherapy alone may be of benefit , particularly for those with lymph-node metastases .
There is insufficient evidence from r and omized trials to recommend neoadjuvant chemotherapy , or neoadjuvant or adjuvant radiotherapy or immunotherapy , either alone or in combination , outside a clinical trial .
OBJECTIVE To make recommendations on the use of neoadjuvant or adjuvant therapy in addition to surgery in patients with resectable gastric cancer ( T1 - 4 , N1 - 2 , M0 ) .
OPTIONS Neoadjuvant or adjuvant treatments compared with " curative " surgery alone .
OUTCOMES Overall survival , disease-free survival , and adverse effects .
The radiation fields used can possibly damage the left kidney , result ing in hypertension and other renal problems .